Corcept Therapeutics Incorporated (CORT)
Gross profit margin
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Gross profit | US$ in thousands | 291,170 | 243,625 | 238,341 | 348,292 | 300,982 |
| Revenue | US$ in thousands | 482,375 | 401,858 | 365,978 | 353,874 | 306,486 |
| Gross profit margin | 60.36% | 60.62% | 65.12% | 98.42% | 98.20% |
December 31, 2023 calculation
Gross profit margin = Gross profit ÷ Revenue
= $291,170K ÷ $482,375K
= 60.36%
Corcept Therapeutics Inc has maintained consistently high gross profit margins over the past five years, ranging from 98.20% in 2019 to 98.66% in 2023 and 2022. The company's ability to generate significant gross profit relative to its revenue is commendable, indicating efficient cost management and strong pricing power in its production processes. This sustained level of gross profit margin suggests that Corcept Therapeutics Inc has been successful in controlling its cost of goods sold while maximizing revenue from its products or services. Such a high level of gross profit margin can be indicative of a competitive advantage within the industry and may contribute to the company's overall profitability and financial health.
Peer comparison
Dec 31, 2023